** Shares of Healius Ltd have gained 13% so far this week; set for best weekly gain since Dec. 1, if trend holds
** Healthcare firm on Tuesday said it would start a review and engage investment advisers, after regulator rejected a $1 bln takeover by Australian Clinical Labs last year
** Co also announced change in CEO to lead the strategic review
** Co said proceeds from the sale will increase its CET1 ratio by 16 basis points
** Stock up as much as 3.1% at A$1.35 on the day
** Stock down 19.9% YTD, as of last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments